Titan Pharmaceuticals Inc (TTNP)

[F1ash]

"In the second quarter of 2016, Titan recognized just over four thousand dollars of royalty revenue from the sale of Probuphine. Despite being a small amount, We were pleased to see some product sales in the second quarter as this was ahead of our target for early third quarter. We anticipate that revenues will increase sharply in the third and fourth quarters and forecast Probuphine royalty revenues of $1.4 million for the full year. In 2017, as key providers are trained and identify appropriate patients for the therapy, and become more comfortable with the product and implantation, we anticipate growth to $17 million in Probuphine revenues. As partner Braeburn has taken over the operational costs of launching Probuphine, operating expenditures for Titan are focused on the company’s emerging programs for Parkinson’s Disease (ropinirole) and hypothyroidism (triiodothyronine). We anticipate that second half R&D will increase as these programs come more to the forefront."

http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2016/TTNP-Probuphine-Sales-in-2Q16-Provider-Training-On-Track/default.aspx